Drug Trial Radar · NCT07108283
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
207
Actual
Start
Nov 3, 2025
Primary completion
Mar 26, 2027
Study completion Nov 9, 2027
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Aug 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches). The main aim of this study is to learn how safe zasocitinib is, how well it works and how well it is tolerated by adults with nonsegmental vitiligo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 1 year (52 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. Participants who receive placebo at the beginning will change to zasocitinib after about 6 months. During the study, participants will visit their study clinic 11 times.
Conditions
- Nonsegmental Vitiligo
Interventions
ZasocitinibDrug
Zasocitinib capsules.
PlaceboOther
Zasocitinib matching placebo capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving >= 75% Improvement From Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24Time frame: Baseline, Week 24
Locations
67 sites in 9 countries. Site status is shown where the registry gives one.
Dermatology Trial Associates
Bryant, Arkansas
First OC Dermatology
Fountain Valley, California
Center for Dermatology Clinical Research, Inc.
Fremont, California
The Vitiligo & Pigmentation Institute of Southern California
Los Angeles, California
UC Davis Department of Dermatology
Sacramento, California
Therapeutics Clinical Research
San Diego, California
Encore Medical Research of Boynton Beach LLC.
Boynton Beach, Florida
San Marcus Research Clinic, Inc.
Miami Lakes, Florida
Advanced Clinical Research Institute (ACRI)
Tampa, Florida
Encore Medical Research of Weston LLC
Weston, Florida
DelRicht Research - Dermatology
Baton Rouge, Louisiana
DelRicht Research (Audubon Dermatology)
New Orleans, Louisiana
Lawrence J Green LLC
Rockville, Maryland
Hamzavi Dermatology - Canton
Canton, Michigan
Weill Cornell Medicine
New York, New York
Markowitz Medical dba Optiskin
New York, New York
Medical University of South Carolina
Charleston, South Carolina
UT Health Science Center Houston
Bellaire, Texas
ACRC Trials
Plano, Texas
Progressive Clinical Research-San Antonio
San Antonio, Texas
Texas Dermatology and Laser Specialists
San Antonio, Texas
Brunswick Dermatology Center (BDC)
Fredericton, New Brunswick, Canada
SimcoDerm Medical and Surgical Dermatology Centre
Barrie, Ontario, Canada
LEADER research
Hamilton, Ontario, Canada
The Centre for Clinical Trials
Oakville, Ontario, Canada
SKiN Centre for Dermatology
Peterborough, Ontario, Canada
North York Research Inc
Toronto, Ontario, Canada
Centre de Recherche Dermatologique de Quebec
Québec, Quebec, Canada
Skinsense Medical Research
Saskatoon, Saskatchewan, Canada
The First Hospital of Wuhan
Wuhan, Hubei, China
First Affiliated Hospital of Xi 'an Jiaotong University
Xi'an, Shaanxi, China
Huashan Hospital of Fudan University
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Kunming Medical College
Kunming, Yunnan, China
Hangzhou Third People's Hospital
Hangzhou, Zhejiang, China
Bordeaux University Hospital
Bordeaux, France
Assistance Publique-Hopitaux de Paris (AP-HP) - Hopitaux Universitaires Henri Mondor (Hopital Henri-Mondor)
Créteil, France
Centre Hospitalier Le Mans (CHM)
Le Mans, France
Cabinet Medical du Dr Ruer
Martigues, France
Centre Hospitalier Universitaire de Nice - Hopital l'Archet
Nice, France
Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital Larrey
Toulouse, France
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.